AIM ImmunoTech is trading 5.8% up now at $0.24 after announcing a broad U.S. patent covering Ampligen combined with pembrolizumab for cancer treatment.
- The patent spans multiple oncology indications and expires December 20, 2039.
- It strengthens the company’s long-term intellectual-property position.
- The company-specific catalyst outweighs weak biotechnology-sector sentiment, with XBI down 4.24% and broader markets also lower.